<DOC>
	<DOC>NCT02989168</DOC>
	<brief_summary>This is an open label study in which eligible IPF subjects who are using supplemental oxygen at rest will receive GBT440 orally daily.</brief_summary>
	<brief_title>Study to Evaluate the Effect of GBT440 Administered to Subjects With IPF on Supplemental Oxygen at Rest</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>Documented diagnosis of IPF. Receiving supplemental oxygen for use at rest. Weight â‰¥ 40 kg. Male or female of child bearing potential willing and able to use highly effective methods of contraception from study start to 30 days after the last dose of study drug. FEV1/FVC &lt; 70% History of other interstitial lung diseases. Subject plans to begin or has commenced pulmonary rehabilitation within 30 days of screening. Corticosteroid (&gt; 10 mg per day of prednisone or an equivalent) administered for 7 days or longer, within 30 days of screening. Participated in another clinical trial of an investigational drug (or medical device) within 30 days or 5halflives, whichever is longer, prior to screening, or is currently participating in another trial of an investigational drug (or medical device). Female who is breastfeeding or pregnant Current smoker or history of smoking within 3 months from screening</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Idiopathic pulmonary fibrosis</keyword>
	<keyword>hypoxemia</keyword>
	<keyword>oxygen</keyword>
</DOC>